Takeda Pharmaceutical (NYSE:TAK) Hits New 1-Year High – Still a Buy?

Takeda Pharmaceutical Co. (NYSE:TAK) shares hit a new 52-week high on Monday . The company traded as high as $16.58 and last traded at $16.5690, with a volume of 223839 shares changing hands. The stock had previously closed at $16.29.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TAK. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research report on Monday, December 29th. Morgan Stanley initiated coverage on Takeda Pharmaceutical in a report on Tuesday, January 13th. They set an “overweight” rating for the company. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Takeda Pharmaceutical presently has an average rating of “Hold”.

Takeda Pharmaceutical Trading Up 1.5%

The company has a quick ratio of 0.76, a current ratio of 1.37 and a debt-to-equity ratio of 0.61. The company’s 50-day moving average is $15.13 and its 200 day moving average is $14.74. The company has a market cap of $52.61 billion, a price-to-earnings ratio of 206.69 and a beta of 0.03.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.44 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.44. Takeda Pharmaceutical had a net margin of 0.86% and a return on equity of 10.32%. The business had revenue of $7.30 billion during the quarter, compared to the consensus estimate of $8.01 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.250-3.250 EPS. Research analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Institutional Trading of Takeda Pharmaceutical

Institutional investors and hedge funds have recently made changes to their positions in the business. Twin Peaks Wealth Advisors LLC acquired a new position in shares of Takeda Pharmaceutical during the 2nd quarter worth approximately $28,000. Evelyn Partners Investment Management LLP increased its holdings in Takeda Pharmaceutical by 163.4% in the 2nd quarter. Evelyn Partners Investment Management LLP now owns 2,515 shares of the company’s stock worth $39,000 after acquiring an additional 1,560 shares in the last quarter. True Wealth Design LLC lifted its holdings in Takeda Pharmaceutical by 1,262.3% during the third quarter. True Wealth Design LLC now owns 2,711 shares of the company’s stock valued at $40,000 after purchasing an additional 2,512 shares in the last quarter. NewSquare Capital LLC grew its position in shares of Takeda Pharmaceutical by 182.4% in the second quarter. NewSquare Capital LLC now owns 3,451 shares of the company’s stock valued at $53,000 after purchasing an additional 2,229 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its position in shares of Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares during the period. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.